The english version of the website is under development. Wherever text appears in Greek, it means it has not been translated yet.

Δημοσίευση

Matrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.

TitleMatrix Gelatinases in Atherosclerosis and Diabetic Nephropathy: Progress and Challenges.
Publication TypeJournal Article
Year of Publication2017
AuthorsDimas, G. G., Didangelos T. P., & Grekas D. M.
JournalCurr Vasc Pharmacol
Volume15
Issue6
Pagination557-565
Date Published2017
ISSN1875-6212
KeywordsAnimals, Atherosclerosis, Diabetic Nephropathies, Gelatinases, Humans, Matrix Metalloproteinase 2, Matrix Metalloproteinase 9
Abstract

BACKGROUND: Matrix metalloproteinases (MMPs) are zinc-dependent proteases that degrade components of the extracellular matrix (ECM). In glomerular disease, MMPs are major regulators of ECM degradation as well as structural and functional integrity in the glomerulus. In altered matrix composition diseases, glomerular damage is due to increased degradation of kidney and vessel basement membranes (BMs) by MMPs. MMP -2 and -9 are both considered as the main enzymes that degrade collagen type-IV (coll-IV), which represents the key collagenous component of ECM and constitutes the architectural structure of vessels and glomerular BM. There is growing evidence implicating MMPs in atherosclerosis as well as in cardiovascular disease (CVD) and chronic kidney disease (CKD). Specific endogenous tissue inhibitors of MMPs (TIMPs) are also implicated in CKD, CVD and diabetic nephropathy (DN).CONCLUSION: The present review discusses the role of MMPs -2 and -9 in DN, as a leading cause of endstage renal disease and as a model of the link between progressive glomerulosclerosis and MMP expression.

DOI10.2174/1570161115666170202162345
Alternate JournalCurr Vasc Pharmacol
PubMed ID28155628

Contact

Secretariat of the School of Medicine
 

Connect

School of Medicine's presence in social networks
Follow Us or Connect with us.